AZD-1152HQPA Barasertib

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：AZD-1152HQPA Barasertib	Purity：98% min
CAS NO：722544-51-6	Solubility：DMSO: 100 mg/mL (197.02 mM)
Molecular Formula：C₂₆H₃₀FN₇O₃	Package：Package according to customer requirements
Molecular Weight：507.560	Storage：Store at -20℃

Quality control

Remarks

AZD-1152 HQPA is a potent and selective Aurora B inhibitor (IC50 of 0.37 nM versus 1368 nM for Aurora B and A kinases, respectively) and is also an active metabolite of Barasertib ( AZD-1152). Barasertib is a prodrug and will be converted rapidly to the active drug AZD1152-HQPA in human plasma. Preliminary studies showed that AZD-1152 was active against a variety of solid tumors including colon, breast, and lung cancers. IMPORTANT NOTE: AZD-1152HQPA IS NOT AZD-1152 or Barasertib. Many vendors is selling Barasertib with wrong structure

Related Products:

SRT1720 hcl; ABT-751; MK-5108; SNS-314; SNS-314 mesylate; Alisertib; Abexinostat; Romidepsin; R547; Tubastatin A HCL; SCH900776; PF00477736; GW7647; Dalcetrapib

References

[1]. Wilkinson RW, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res. 2007 Jun 15;13(12):3682-8.

[2]. Yang, Jing., et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood. 2007 Sep 15;110(6):2034-40.